Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153229 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
A Phase 2 study of Epitheliod Malignant Pleural Mesothelioma, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT02153229: Active Phase 2 study of Epitheliod Malignant Pleural Mesothelioma, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02153229 is a Phase 2 study of Epitheliod Malignant Pleural Mesothelioma that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 52 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02153229, a Phase 2 study of Epitheliod Malignant Pleural Mesothelioma, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior to surgery . All subjects will receive maximal surgical debulking. Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic light dosimetry.
Conditions Studied
Interventions
- RADIATION Photodynamic Therapy
- PROCEDURE Radical Pleurectomy
- RADIATION Chemotherapy
- DRUG Photofrin 2.0 mg/kg
Study Locations (2)
New York
- Roswell Park Cancer Institute - Buffalo
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-06-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What the registry record for NCT02153229 still lists
NCT02153229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Epitheliod Malignant Pleural Mesothelioma appearing as the primary indexed condition, and to 4 interventions - of which Photodynamic Therapy is the first listed.
NCT02153229 reports a single indexed study location in New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02153229 about?
NCT02153229 is a clinical study titled "Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma". A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior t...
What is the current status of trial NCT02153229?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2014-06-02. Estimated completion is 2027-12.
What conditions does trial NCT02153229 study?
This clinical trial studies the following conditions: Epitheliod Malignant Pleural Mesothelioma.
What interventions are being tested in trial NCT02153229?
The interventions under investigation include: Photodynamic Therapy (RADIATION), Radical Pleurectomy (PROCEDURE), Chemotherapy (RADIATION), Photofrin 2.0 mg/kg (DRUG).
Who is sponsoring clinical trial NCT02153229?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02153229 being conducted?
This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02153229's enrollment target sits among peer trials
52 1181st of 2000 higher than 811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI